Floatz logo

PTEROYLMONOGLUTAMIC ACID HYDROLASE G2

Neurotoxicity

University College, Londonprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Neurotoxicity cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Radiation Therapy Oncology Group
Phase 2BB
ERIBULIN MONOMETHANESULFONATE
Oncologia Medica dell'Ospedale Fatebenefratelli
Phase 4BB
Procarbazine
Radiation Therapy Oncology Group
Phase 2BB
Amitriptyline
Alliance for Clinical Trials in Oncology
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

PTEROYLMONOGLUTAMIC ACID HYDROLASE G2 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
lymphomaDormant
B
Indicative ·
59 / 100
View asset →
mucositisDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →